Target type: biologicalprocess
Any process that mediates the transfer of information from an AV node cardiac muscle cell to a bundle of His cardiomyocyte. [GOC:BHF, GOC:mtg_cardiac_conduct_nov11]
The atrioventricular (AV) node, situated between the atria and ventricles of the heart, plays a crucial role in regulating the heart's rhythm. Its primary function is to delay the electrical impulse originating from the sinoatrial (SA) node, allowing the atria to contract completely before the ventricles. This delay is achieved through the unique properties of AV node cells.
AV node cells, unlike other cardiac cells, possess a slower rate of depolarization and a longer action potential duration. These characteristics are attributed to their specialized ion channels, which permit a slower influx of sodium and calcium ions and a prolonged efflux of potassium ions. This slower conduction velocity is crucial for ensuring coordinated contraction of the atria and ventricles.
The signal transmission from AV node cells to bundle of His cells, the first component of the ventricular conduction system, is facilitated by the AV node's unique structure and cellular properties. The AV node is composed of specialized cells arranged in a compact structure, resembling a small bundle of fibers. These cells are interconnected by gap junctions, which allow for the rapid flow of ions and electrical signals between adjacent cells.
As the electrical impulse from the SA node reaches the AV node, it triggers a series of events. The impulse first travels through the AV node's upper part, termed the "junctional region", and then enters the "central region", characterized by a slow conduction velocity. This slow conduction is essential for allowing atrial contraction to complete before the ventricles contract. Subsequently, the impulse travels through the "inferior region" of the AV node, where it reaches the bundle of His.
The bundle of His, a group of specialized fibers located at the base of the AV node, acts as a conduit for the electrical signal to the ventricles. The signal then diverges into the right and left bundle branches, which further divide into smaller branches known as Purkinje fibers. These fibers spread throughout the ventricular myocardium, initiating ventricular contraction.
The signaling process from the AV node to the bundle of His involves a complex interplay of ion channels, membrane potentials, and cellular interactions. This intricate mechanism ensures that the electrical impulse is efficiently and accurately transmitted from the atria to the ventricles, maintaining proper heart rhythm and enabling coordinated cardiac function.
'"
Protein | Definition | Taxonomy |
---|---|---|
Voltage-dependent T-type calcium channel subunit alpha-1G | A voltage-dependent T-type calcium channel subunit alpha-1G that is encoded in the genome of human. [PRO:WCB, UniProtKB:O43497] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
tacrine | tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease. Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. | acridines; aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor |
nimodipine | nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm. Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. | 2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester | antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent |
pimozide | pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) | benzimidazoles; heteroarylpiperidine; organofluorine compound | antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist |
mibefradil | Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE. | tetralins | T-type calcium channel blocker |
vexibinol | sophoraflavanone G : A tetrahydroxyflavanone having a structure of naringenin bearing an additional hydroxyl substituent at position 2' as well as a (2R)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl (lavandulyl) substituent at position 8'. vexibinol: flavanol from Sophora; structure in first source; RN given refers to (S-(R*,S*))-isomer | (2S)-flavan-4-one; 4'-hydroxyflavanones; tetrahydroxyflavanone | antimalarial; antimicrobial agent; antioxidant; plant metabolite |
8-prenylnaringenin | 8-prenylnaringenin: a phytogenic antineoplastic agent; structure in first source sophoraflavanone B : A trihydroxyflavanone that is (S)-naringenin having a prenyl group at position 8. | (2S)-flavan-4-one; 4'-hydroxyflavanones; trihydroxyflavanone | plant metabolite; platelet aggregation inhibitor |
flunarizine | Flunarizine: Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. | diarylmethane | |
2-phenoxy-N-[5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,4-oxadiazol-2-yl]acetamide | tetralins | ||
(S)-4',5,7-Trihydroxy-6-prenylflavanone | flavanones | ||
ith 4012 | |||
kys 05090 | |||
ulixacaltamide | Z944: a T-type calcium channel antagonist | benzamides; monochlorobenzenes; monofluorobenzenes; piperidines; secondary carboxamide | non-narcotic analgesic; T-type calcium channel blocker |